Editorial policy.

A Peptide House note starts with one question and annotates the evidence that answers it. These are the rules each note follows.

Naming the evidence

Every claim is tagged by what supports it: an approved label, a phased human trial, a case report, an animal or cell experiment, or an opinion. A rodent result is never written up as if it happened in people.

Where facts come from

The 27 longer notes were fact-checked against PubMed and PubMed Central records, ClinicalTrials.gov, FDA labels and DailyMed, regulator and anti-doping publications and established medical news, and those checked sources appear under each note. The 12 short introductory notes from the first batch were written as general explainers and do not carry a source list yet. Seller pages, clinic marketing and forums are never used as evidence.

Doses

Readers search for dosage, and several titles use the word. The notes answer with what trials used, what labels state and, where nothing is approved, the plain statement that no human dose has been established. They give no personal dosing advice and no schedules for self-use.

Independence

There are no advertisers, sponsors or affiliate programmes, and no seller is named as a source of any product. Notes are published under the Peptide House name; the site does not invent bylines or credentials.

Corrections

Confirmed errors are fixed in the note itself, and the "Last reviewed" date appears once a note has really been edited. Send corrections through the contact page, with the source you checked.